Braxia Scientific Corp (OTCMKTS:BRAXF) Stock Falls 7% In a Week: What’s The Buzz?
Braxia Scientific Corp (OTCMKTS:BRAXF) is down 7% in a week. The medical research firm with clinics offering psychedelic treatment to people with depression and other behavioral disorders has achieved the first approved multiple-dose psilocybin clinical study and has dosed the first patients in November 201.
Market Stats
On Tuesday, BRAXF stock slid 1% to $0.0758 with more than 381k shares, compared to its average volume of 393k shares. The stock has moved within a range of $0.0750 – 0.0781 after opening trading at $0.0781.
Major News
The Brain and Cognition Discovery Foundation-sponsored study is ongoing at Braxia’s wholly-owned subsidiary, the Canadian Rapid Treatment Centre of Excellence. The study includes individuals with treatment-resistant depression as part of unipolar or bipolar disorder who are resistant to several conventional therapies. Notably, this is the first Health-Canada authorized psilocybin study in Canada that is enrolling subjects.
CEO Roger McIntyre said this is a historic occasion for the company, patients, and organizations looking to identify and create innovative fast-acting psychedelic therapy for mental health problems. Notably, the remedy offers innovativetreatment alternatives for adults with treatment-resistant depression who have undergone more than two unsuccessful standard treatments. So, BRAXF is worth watching.
Traders Corner
BRAXF stock is trading below the 20-Day and 50-Day Moving averages of $0.0917 and $0.1230 respectively. The stock is trading in neutral zone with the RSI at 30. The stock is up 74% in the past 6-month.
